Arbutus Biopharma ABUS
NASDAQ ABUS
$4.78 +0.09 (+1.92%)
At close: Sep 30, 2026 · 4:00 PM EDT

Arbutus Biopharma (ABUS) Cash from Financing Activities (2013 - 2026)

Updated

Arbutus Biopharma (ABUS) posted Cash from Financing Activities of $3.15 million for Q2 2026, up 594.9% from $453,000 a year earlier but down 72.9% from the prior quarter.

Analysis

Arbutus Biopharma (ABUS) Cash from Financing Activities (2013 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Cash from Financing Activities at Arbutus Biopharma was $17.25 million, up 168.2% year-over-year; for FY2025, it was $5.72 million, down 89.0% from FY2024.

  • Annual Cash from Financing Activities shows a five-year compound annual growth rate of -41.9% (FY2020 to FY2025).
  • In prior years, Arbutus Biopharma's Cash from Financing Activities was $52 million in FY2024 (+69.7%), $30.65 million in FY2023 (-3.7%), $31.81 million in FY2022 (-76.8%) and $137.24 million in FY2021 (+58.2%).
  • Quarterly Cash from Financing Activities has run from a low of $113,000 in Q2 2022 to a high of $59.12 million in Q4 2021 over five years.
  • On a year-over-year basis, Cash from Financing Activities has increased in each of the last three quarters, with growth averaging 78.9% over the last eight quarters.
  • The strongest year-over-year quarter for Cash from Financing Activities in the past five years was Q2 2026, with growth of 594.9%; the weakest was Q2 2025, with a decline of 98.1%.
  • According to Business Quant data, Cash from Financing Activities for the three prior quarters was $11.62 million (Q1 2026), $1.64 million (Q4 2025) and $844,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -8.78 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -5.05 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 1.76 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -2.02 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -47.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -1.48 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 2.34 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -3.66 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -426.70 Mn
10 Arbutus Biopharma 944.69 Mn 571.67 Mn - 3.15 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3.15 Mn
Mar 31, 2026 11.62 Mn
Dec 31, 2025 1.64 Mn
Sep 30, 2025 844,000.00
Jun 30, 2025 453,000.00
Mar 31, 2025 2.78 Mn
Dec 31, 2024 1.42 Mn
Sep 30, 2024 1.78 Mn
Jun 30, 2024 24.37 Mn
Mar 31, 2024 24.43 Mn
Dec 31, 2023 3.81 Mn
Sep 30, 2023 1.68 Mn
Jun 30, 2023 4.74 Mn
Mar 31, 2023 20.42 Mn
Dec 31, 2022 11.08 Mn
Sep 30, 2022 9.13 Mn
Jun 30, 2022 113,000.00
Mar 31, 2022 11.49 Mn
Dec 31, 2021 59.12 Mn
Sep 30, 2021 46.95 Mn
API Access

Arbutus Biopharma Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=ABUS&period=max&api_key=YOUR_API_KEY